7-羟基-(3S)-1,2,3,4-四氢异喹啉-3-羧酸甲酯 | 477533-63-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 7-羟基-(3S)-1,2,3,4-四氢异喹啉-3-羧酸甲酯
• 英文名称: methyl (S)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• 英文别名: (S)-methyl 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate；(S)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester；methyl 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-(3S)-carboxylate；7-hydroxy-(3S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester；Methyl (3S)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
• CAS: 477533-63-4
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: JHAHRGPSCUPBIB-JTQLQIEISA-N

物化性质

• 沸点：
  367.0±42.0 °C(Predicted)
• 密度：
  1.231±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-羟基-(3S)-1,2,3,4-四氢异喹啉-3-羧酸甲酯 在 lithium hydroxide 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Novel Dmt-Tic dipeptide analogues as selective delta-opioid receptor antagonists

  摘要：

  A series of Dmt-Tic analogues with substitution on the Tic aromatic ring has been synthesized and evaluated for opioid receptor affinity and activation. Incorporation of large hydrophobic groups at position 7 of Tic did not greatly alter the delta opioid receptor binding affinities of the dipeptides whereas substitution at position 6 substantially diminished their affinity. These modified Dmt-Tic peptides showed binding affinities as low as 2.5 nM with up to 500-fold selectivity for the delta versus mu opioid receptor and proved to be 6 receptor antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00652-6
• 作为产物：
  描述：

  L-7-羟基-1,2,3,4-四氢异喹啉-3-羧酸 在 盐酸 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 溶剂黄146 、 苯 为溶剂， 反应 17.5h， 生成 7-羟基-(3S)-1,2,3,4-四氢异喹啉-3-羧酸甲酯
  参考文献：
  名称：

  Novel Dmt-Tic dipeptide analogues as selective delta-opioid receptor antagonists

  摘要：

  A series of Dmt-Tic analogues with substitution on the Tic aromatic ring has been synthesized and evaluated for opioid receptor affinity and activation. Incorporation of large hydrophobic groups at position 7 of Tic did not greatly alter the delta opioid receptor binding affinities of the dipeptides whereas substitution at position 6 substantially diminished their affinity. These modified Dmt-Tic peptides showed binding affinities as low as 2.5 nM with up to 500-fold selectivity for the delta versus mu opioid receptor and proved to be 6 receptor antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00652-6

文献信息

• Design, Synthesis, and Structure–Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibody–Drug Conjugates
  作者：Naidu S. Chowdari、Yong Zhang、Ivar McDonald、Walter Johnson、David R. Langley、Prasanna Sivaprakasam、Robert Mate、Tram Huynh、Srikanth Kotapati、Madhura Deshpande、Chin Pan、Daniel Menezes、Yichong Wang、Chetana Rao、Ganapathy Sarma、Bethanne M. Warrack、Vangipuram S. Rangan、Sung Mei-Chen、Pina Cardarelli、Shrikant Deshpande、David Passmore、Richard Rampulla、Arvind Mathur、Robert Borzilleri、Arvind Rajpal、Gregory Vite、Sanjeev Gangwar

  DOI：10.1021/acs.jmedchem.0c01385

  日期：2020.11.25

  series of tetrahydroisoquinoline-based benzodiazepine dimers were synthesized and tested for in vitro cytotoxicity against a panel of cancer cell lines. Structure–activity relationship investigation of various spacers guided by molecular modeling studies helped to identify compounds with picomolar activity. Payload 17 was conjugated to anti-mesothelin and anti-fucosylated monosialotetrahexosylganglioside

  合成了一系列基于四氢异喹啉的苯并二氮杂二聚体，并测试了其对一组癌细胞系的体外细胞毒性。通过分子建模研究指导的各种间隔基的结构-活性关系研究有助于鉴定具有皮摩尔活性的化合物。有效负载17通过溶酶体可裂解的缬氨酸-瓜氨酸二肽接头，通过异源赖氨酸偶联和细菌转谷氨酰胺酶介导的位点特异性偶联，将其与抗间皮素和抗岩藻糖基化的单唾液酸四己糖基神经节苷脂（FucGM1）抗体偶联。在体外，这些抗体药物偶联物（ADC）对人类癌细胞系表现出显着的细胞毒性和靶标介导的选择性。在小鼠的胃癌和肺癌异种移植模型中，进一步评估了这些ADC的药代动力学和功效。在单剂量ADC- 46（0.02μmol / kg）之后，在这些模型中观察到一致的药代动力学特征，高靶标特异性和强大的抗肿瘤活性。
• 2-Acyl-3-carboxyl-tetrahydroisoquinoline Derivatives: Mixed-Type PTP1B Inhibitors without PPARγ Activation
  作者：Ko Morishita、Yoshimichi Shoji、Masaki Fukui、Yuma Ito、Tatsuya Kitao、Shin-ichiro Ozawa、Shuichi Hirono、Hiroaki Shirahase

  DOI：10.1248/cpb.c18-00571

  日期：2018.12.1

  oquinoline derivatives were synthesized and biologically evaluated. Among them, (S)-2-(E)-3-furan-2-ylacryloyl}-7-[(2E,4E)-5-(2,4,6-trifluorophenyl)penta-2,4-dienyloxy]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (compound 17u) was identified as a potent protein tyrosine phosphatase 1B (PTP1B) inhibitor without peroxisome proliferator-activated receptor (PPAR) γ activation: PTP1B inhibition IC50=0

  合成了一系列新颖的2-酰基-3-羧基-四氢异喹啉衍生物，并对其进行了生物学评估。其中，（S）-2-（（E）-3-呋喃-2-基丙烯酰基）-7-[（2E，4E）-5-（2,4,6-三氟苯基）戊-2,4-二烯氧基] -1,2,3,4-四氢异喹啉-3-羧酸（化合物17u）被确定为有效的蛋白酪氨酸磷酸酶1B（PTP1B）抑制剂，无过氧化物酶体增殖物激活受体（PPAR）γ激活：PTP1B抑制作用IC50 = 0.19 µM，PPARγEC50> 10 µM。化合物17u对PTP1B表现出混合型抑制作用，这种抑制模式通过计算配体对接到PTP1B的催化位点和变构位点而得以合理化。化合物17u在大鼠中也表现出较高的口服吸收，剂量为10 mg / kg（每os（口服），Cmax = 4.67 µM），在以db的最终给药后24小时进行的口服葡萄糖耐量试验中，在30 mg / kg / d（po）下连续4周显着
• [EN] MU OPIOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR OPIOÏDE DE TYPE MU
  申请人：UNIV CALIFORNIA

  公开号：WO2018129393A1

  公开（公告）日：2018-07-12

  Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

  本文描述了用于调节μ阿片受体活性的组合物和方法。
• CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S
  申请人：Ameriks Michael K.

  公开号：US20080200454A1

  公开（公告）日：2008-08-21

  Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.

  描述了与碳相连的四氢吡唑吡啶化合物，这些化合物可作为cathepsin S调节剂。这些化合物可用于制备药物组合物和治疗疾病状态、疾病和病况的方法，这些疾病状态、疾病和病况是由cathepsin S活性介导的，如银屑病、疼痛、多发性硬化症、动脉粥样硬化和类风湿性关节炎。
• PROCESS FOR THE SYNTHESIS OF SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES
  申请人：Senomyx, Inc.

  公开号：US20150223503A1

  公开（公告）日：2015-08-13

  The present invention relates to processes and intermediates for the preparation of compounds of formula (I): or a salt or oxide thereof, wherein Alk, M 1 , M 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and n are as described herein. The present invention also relates to compounds of formula (I) and composition comprising a compound of formula (I). Also disclosed is a method of altering or improving the taste of a composition that includes adding to the composition at least one compound of formula (I), in an amount effective to obtain a modified composition having altered or improved taste relative to an otherwise identical composition lacking said compound.

  本发明涉及用于制备化合物的过程和中间体的方法的中间体，其化学式为（I）：或其盐或氧化物，其中Alk，M1，M2，R1，R2，R3，R4，R5，R6，R7和n如本文所述。本发明还涉及化合物的化学式（I）以及包含化合物的组合物（I）。还公开了一种改变或改进组合物口味的方法，该方法包括向组合物中添加至少一种化学式（I）的化合物，添加量有效以获得相对于缺少该化合物的相同组合物具有改变或改进口味的改良组合物。